Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $10.50.

Several research firms have recently commented on AGEN. HC Wainwright cut shares of Agenus from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $40.00 to $9.00 in a research note on Thursday, July 18th. William Blair lowered Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. Jefferies Financial Group reissued a “hold” rating and set a $7.00 target price (up from $3.00) on shares of Agenus in a research note on Friday, July 19th. StockNews.com downgraded Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Finally, Robert W. Baird cut Agenus from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $35.00 to $8.00 in a research report on Friday, July 19th.

Agenus Stock Down 6.9 %

AGEN opened at $5.10 on Wednesday. Agenus has a 52 week low of $4.41 and a 52 week high of $23.20. The business has a 50 day moving average price of $5.46 and a two-hundred day moving average price of $9.88. The company has a market cap of $107.09 million, a PE ratio of -0.40 and a beta of 1.36.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The firm had revenue of $23.51 million during the quarter, compared to analyst estimates of $64.73 million. During the same period in the previous year, the business earned ($4.00) EPS. As a group, sell-side analysts expect that Agenus will post -10.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Agenus

Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 DIFC Ltd purchased a new position in Agenus during the 2nd quarter valued at about $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Agenus during the 2nd quarter worth approximately $106,000. Hennion & Walsh Asset Management Inc. raised its position in shares of Agenus by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 13,604 shares during the last quarter. Blair William & Co. IL purchased a new stake in Agenus in the 2nd quarter valued at approximately $441,000. Finally, Squarepoint Ops LLC acquired a new stake in Agenus during the 2nd quarter valued at $614,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.